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Abstract
Background—ACC/AHA Guidelines for the Diagnosis and Management of Heart Failure (HF)
recommend investigating exacerbating conditions, such as thyroid dysfunction, but without
specifying impact of different TSH levels. Limited prospective data exist regarding the association
between subclinical thyroid dysfunction and HF events.
Methods and Results—We performed a pooled analysis of individual participant data using all
available prospective cohorts with thyroid function tests and subsequent follow-up of HF events.
Individual data on 25,390 participants with 216,248 person-years of follow-up were supplied from
6 prospective cohorts in the United States and Europe. Euthyroidism was defined as TSH 0.45–
4.49 mIU/L, subclinical hypothyroidism as TSH 4.5–19.9 mIU/L and subclinical hyperthyroidism
as TSH <0.45 mIU/L, both with normal free thyroxine levels. Among 25,390 participants, 2068
had subclinical hypothyroidism (8.1%) and 648 subclinical hyperthyroidism (2.6%). In age- and
gender-adjusted analyses, risks of HF events were increased with both higher and lower TSH
levels (P for quadratic pattern <0.01): hazard ratio (HR) was 1.01 (95% confidence interval [CI]
0.81–1.26) for TSH 4.5–6.9 mIU/L, 1.65 (CI 0.84–3.23) for TSH 7.0–9.9 mIU/L, 1.86 (CI 1.27–
2.72) for TSH 10.0–19.9 mIUL/L (P for trend <0.01), and was 1.31 (CI 0.88–1.95) for TSH 0.10–
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0.44 mIU/L and 1.94 (CI 1.01–3.72) for TSH <0.10 mIU/L (P for trend = 0.047). Risks remained
similar after adjustment for cardiovascular risk factors.
Conclusions—Risks of HF events were increased with both higher and lower TSH levels,
particularly for TSH ≥10 mIU/L and for TSH <0.10 mIU/L.
Keywords
cohort study; epidemiology; heart failure; meta-analysis; thyroid
Background
Heart failure (HF) is a frequent cause of hospitalization in persons older than 65 years with
an increasing trend in the number of patients living with heart failure.1, 2 Given that HF
constitutes a major public health problem within the context of an aging and growing
population,1, 3–5 recognizing modifiable risk factors for HF events is essential to target
subjects who are at risk for developing this condition.6, 7 The ACC/AHA Guidelines for the
Diagnosis and Management of HF in Adults recommend measurement of thyroid function to
investigate conditions that might exacerbate HF, such as hypothyroidism or
hyperthyroidism, but without specifying the potential impact of different Thyroid
Stimulating Hormone (TSH) levels.8
Subclinical thyroid dysfunction is common, particularly in older individuals, with a
prevalence of subclinical hypothyroidism up to 10% and subclinical hyperthyroidism
between 0.7%–3.2%.9 Subclinical hypothyroidism is defined as a serum TSH concentration
above the upper limit of the reference range with serum free thyroxine (FT4) concentration
within its reference range. Subclinical hyperthyroidism is defined as a serum TSH
concentration below the lower limit of the reference range with serum FT4 and free tri-
iodothyronine (FT3) concentrations within their reference ranges.10, 11 Subclinical
hypothyroidism and subclinical hyperthyroidism have been associated with an increased risk
of coronary heart disease (CHD) events and mortality,12–14 but few prospective data are
available concerning the association of subclinical thyroid dysfunction and the risk of HF
events and the strengths of associations varied.15–18 Subclinical thyroid dysfunction has
been associated with systolic and diastolic cardiac dysfunction.16,19 Small studies have
shown that thyroxine replacement improved measurements of cardiac function in subjects
with subclinical hypothyroidism.20 However, no randomized controlled trials have been
performed to evaluate the therapy effect among individuals with subclinical thyroid
dysfunction with clinical HF outcomes. Currently the evidence for screening and treating
subclinical thyroid dysfunction is limited.10, 21, 22
To clarify the association between subclinical thyroid dysfunction and HF events, we
performed a pooled analysis of individual participant data using all available prospective
cohorts. Analysis of individual participant data from large cohort studies may reconcile
heterogeneity between studies by allowing a common TSH cutoff for subclinical thyroid
dysfunction and further adjustment of similar confounding factors. Individual participant
data analysis is the best method for assessing the impact of the degree of subclinical thyroid
dysfunction (measured by TSH level) and of preexisting HF or cardiovascular disease
(CVD) in subgroups analyses, and reduces potential bias from subgroup analyses derived
from study-level meta-analyses.23, 24
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Methods
Study selection
We updated our previous systematic review13 of articles in any language published from
1950 to June 30 2011, in MEDLINE and EMBASE databases on the association between
subclinical thyroid dysfunction and cardiovascular outcomes, searched bibliographies for
key articles and contacted experts in this field (Supplemental Methods). For this analysis, we
followed predefined inclusion criteria considering only full-text, published longitudinal
cohort studies that fulfilled the following conditions: (1) measurement of TSH levels and
FT4 levels at baseline in adults, (2) systematic follow-up over time, (3) assessment of HF
events, and (4) a control euthyroid group. We excluded studies that only considered persons
taking thyroid medications (antithyroid drug or thyroxine replacement) or with overt thyroid
dysfunction (defined by abnormal TSH and FT4 levels). The updated search for additional
studies until 30 June 30 2011, was independently assessed by 2 authors (BG and PB); any
discrepancy between the authors was resolved by discussion with a third author (NR). The
agreement rate between the 2 reviewers was 99.9% for the first screen (titles and abstracts,
kappa=0.66, confidence interval [CI] 0.62–0.72) and 100% for the full-text screen
(kappa=1.00). The assessment of the methodological quality of included studies was
performed according to previously described criteria.14 Two authors (NR, JG) rated all
studies for quality: methods of outcome adjudication, evaluation of confounders and the
completeness of follow-up. All studies were approved by institutional review boards and all
participants gave written informed consent.
Investigators from eligible studies were contacted to join the Thyroid Studies Collaboration.
We requested data about the baseline thyroid function (TSH and FT4, FT3 if available), HF
outcome data, demographic characteristics (age, gender, race), cardiovascular risk factors
(total cholesterol, diabetes, blood pressure, cigarette smoking), preexisting CVD, preexisting
HF, medication (lipid-lowering, antihypertensive drugs, thyroxine replacement and
antithyroid medication) and other potential confounding variables for HF such as body mass
index (BMI), creatinine and atrial fibrillation (AF).
Definition of Subclinical Thyroid Dysfunction
To maximize comparability of the studies, we used a common definition of subclinical
thyroid dysfunction based on expert reviews,10, 21 definition used in the Cardiovascular
Health Study,16, 25 and a consensus meeting of our Collaboration (International Thyroid
Conference, Paris, 2010). Euthyroidism was defined as a TSH level of 0.45–4.49 mIU/L,
subclinical hypothyroidism as a TSH level of 4.5–19.9 mIU/L and subclinical
hyperthyroidism as a TSH level <0.45 mIU/L, both with normal FT4 levels. Based on
previously described TSH cutoffs13, 16 and expert reviews,10, 21 subclinical hypothyroidism
was subdivided into three groups: TSH 4.5–6.9 mIU/L, 7.0–9.9 mIU/L and 10.0–19.9 mIU/
L, and subclinical hyperthyroidism into two groups: TSH 0.10–0.44 mIU/L and <0.10 mIU/
L. For FT4, we used study-specific cutoffs (Supplemental Table 1),13 because FT4
measurements show greater inter-method variation than TSH assays. As done in a previous
study,13 participants with missing FT4 values were included in the primary analyses and
excluded in the sensitivity analyses, as the vast majority of adults with an abnormal TSH
have subclinical and not overt thyroid dysfunction.26 FT3 was measured in two studies
(Supplemental Table 1)17, 27 and was added to the definition of subclinical hyperthyroidism
in sensitivity analyses. As done in previous studies,12,13,15,27 we performed sensitivity
analyses excluding participants using thyroid medication (thyroxine, antithyroid drug) at
baseline and during follow-up.
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Definition of HF events
To limit outcome heterogeneity, HF events were defined by any acute HF events diagnosed
by a physician, hospitalization and deaths related to HF events, based on all available
documents (symptoms, signs, therapy, chest radiographs) within each cohort (Supplemental
Table 1). The blindness of HF outcomes assessment to baseline thyroid status was evaluated
in each cohort and sensitivity analyses were performed according to HF outcomes
adjudication process by experts. Participants with preexisting HF were included in the
primary analyses, as performed in our previous individual participant data analysis
evaluating CHD outcome,12, 13 and were separately analyzed in stratified analyses to
explore the association between subclinical thyroid dysfunction and incident HF events, as
well as for recurrent HF events.
Potential confounders
Primary analyses were adjusted for age and gender, then for traditional cardiovascular risk
factors (systolic blood pressure, total cholesterol, smoking status, diabetes) that were
available in all cohorts. We further adjusted the multivariable models for other potential
confounding factors, such as creatinine, body mass index, preexisting AF at baseline and
cardiovascular medications (lipid-lowering and antihypertensive treatment).
To explore heterogeneity, we performed predefined stratified analyses according to age,
gender, race, TSH levels, preexisting CVD and preexisting HF. We also performed
sensitivity analyses excluding participants with AF at baseline, a common cause of HF
events.
Statistical analyses
For statistical analyses, we performed 2-stage individual participant data analyses as
recommended24, 28 and used in a recent publication.12, 13 Briefly, we performed separate
Cox proportional hazards models to assess the association of subclinical thyroid dysfunction
with HF events for each cohort (SAS 9.2, SAS Institute Inc, Cary, NC; Stata 12.1,
StataCorp, College Station, TX). The pooled estimates were calculated using random-effects
models based on inverse variance model and summarized with forest plots (Review
Manager 5.1.2, Nordic Cochrane Centre, Copenhagen, Denmark). We tested for linear trend
across TSH and age categories and for interaction according to gender, race, preexisting
CVD and preexisting HF. In post-hoc analysis, we also tested for quadratic patterns across
TSH categories. All tests were 2-sided. We did not perform formal adjustments for multiple
comparisons, which can be conservative for correlated outcomes. However, we recognize
the potential for inflation of the type-I error rate, and interpret nominally significant
(P<0.05) results cautiously, and in context. To assess heterogeneity across studies, we used
the I2 statistic, estimating the proportion of the variance across studies attributed to
heterogeneity rather than chance.29 The proportional hazard assumption was assessed using
graphical methods and Schoenfeld tests (all P > 0.05). We used age- and gender-adjusted
funnel plots to assess for publication bias and the Egger test.30 In some subgroups analyses,
some strata had participants with no HF event and we used penalized likelihood methods to
obtain HRs and CI,31 as in our previous individual participant data analyses.12, 13
Results
Among 5413 identified publications, 6 prospective studies met eligibility criteria and
reported HF events (Supplemental Figure 1); all agreed to provide individual participant
data (Table 1). The final sample consisted of 25,390 participants: 22,674 were euthyroid
(89.3%), 2068 had subclinical hypothyroidism (8.1%) and 648 subclinical hyperthyroidism
(2.6%). The median follow-up was 10.4 years, with a total follow-up of 216,248 person-
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years. During follow-up, 2069 participants had HF events. The quality assessment of these
studies showed that all studies had a loss of follow-up ≤5% and all outcome adjudicators
were blinded for thyroid status. A formal adjudication was done in 3
studies, 15, 16, 18 18while other cohorts relied on hospital discharge17, 32 or general
practitioners’ medical records 27 (Supplemental Table 1).
In age- and gender-adjusted analyses, the risk of HF increased in participants with both
higher and lower TSH levels (Figure 1) with a significant test for parabolic function across
TSH categories (P for quadratic pattern < 0.01). For subclinical hypothyroidism compared to
euthyroidism, HR was 1.01 (CI, 0.81–1.26) for TSH 4.5–6.9 mIU/L, 1.65 (CI, 0.84–3.23)
for TSH 7.0–9.9 mIU/L and 1.86 (CI, 1.27–2.72) for TSH 10.0–19.9 mIUL/L (P for trend
across higher TSH categories < 0.01). For subclinical hyperthyroidism compared to
euthyroidism, HR was 1.31 (CI 0.88–1.95) for TSH 0.1–0.44 mIU/L and 1.94 (CI 1.01–
3.72) for TSH <0.10 mIU/L (P for trend across lower TSH categories = 0.047).
Among all participants with subclinical hypothyroidism (Table 2), HR for HF events was
1.26 (95% CI, 0.91–1.74) in age- and gender-adjusted analyses with heterogeneity (I2=77%)
across studies (Supplemental Figure 2). The risk seemed to be higher in younger
participants, but the number of events was small and therefore results were possibly not
significant. Among older participants (≥80 years old), HF events were not increased and the
interaction test across age categories was not significant (P value > 0.10). We found slightly
higher risks in men and Caucasians but without significant interaction test (P value > 0.10),
as well as for preexisting CVD or preexisting HF. Risks were similar after further
adjustment for cardiovascular risk factors, although the strength of the association was
attenuated, with HR remaining significant among those with TSH levels ≥ 10.0 mIU/L (HR
1.59, CI 1.15–2.19). Sensitivity analyses (Table 3) yielded similar results. After excluding
participants using thyroid medication at baseline and during follow-up, the association was
stronger among those with TSH between 10.0 and 19.9 mIU/L (HR 2.37, CI 1.59–3.54).
Risks remained elevated among those with TSH ≥ 10.0 mIU/L after excluding those with
missing FT4 values, after further adjustment for additional HF risk factors (creatinine, body
mass index and preexisting AF) and after excluding those with preexisting AF. After
excluding the Bari study (all with preexisting HF), 17 HR decreased to 1.62 (CI 1.15–2.29)
with a low heterogeneity (I2=0%). 29 Risks were lower after limiting the analyses to cohorts
with formal adjudication procedures by experts; this analysis was only possible for three
studies of older adults (Supplemental Table 1).
Among all participants with subclinical hyperthyroidism (Table 4), HR for HF events in
age- and gender-adjusted analyses was 1.46 (CI 0.94–2.27) compared to euthyroidism with
heterogeneity (I2=61%) across studies (Supplemental Figure 3). In contrast to subclinical
hypothyroidism, the risk was significantly increased among participants ≥ 80 years (HR
2.34, CI 1.27–4.31), but there was not significant trend across age categories (P=0.98). We
found higher risks among women and Caucasians, but the interaction test was not significant
(P >0.30), as well as for preexisting CVD or preexisting HF. Risks were similar after further
adjustment for cardiovascular risk factors.
Among participants with TSH < 0.10 mIU/L, HR for HF events was 1.94 (CI 1.01–3.72) in
age- and gender-adjusted analyses. In sensitivity analysis (Supplemental Table 2), excluding
those with thyroid medication at baseline, HR was 1.80 mIU/L (CI 1.04–3.13). Risks were
similar after further adjustments for HF potential confounding risk factors (body mass index,
creatinine and AF), after excluding those with missing FT4 or abnormal FT3, and after
excluding those with preexisting HF or preexisting AF.
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We found limited evidence of publication bias with visual assessment of age- and gender
adjusted funnel plots, although the Bari study might be an outlier with no corresponding
negative study of similar size, and with Egger test for subclinical hypothyroidism (P=0.23)
and for subclinical hyperthyroidism (P=0.60), although such analyses were limited by the
small number of included studies.
Discussion
In this individual data analysis of 25,390 participants from 6 prospective cohorts, risks of
HF events were increased with higher and lower TSH levels than normal range, with
statistically significant increased risks among those with TSH ≥ 10.0 mIU/L (HR 1.86, CI
1.27–2.72) and those with TSH <0.10 mIU/L (HR 1.94, CI 1.01–3.72). The HF risks were
mainly explained by the degree of thyroid dysfunction, with an observed parabolic
association between TSH levels and risk of HF events (P for quadratic pattern < 0.01). The
increased risk of HF in adults for TSH ≥10.0 mIU/L persisted after excluding those with
preexisting HF or preexisting AF. Further adjustment for cardiovascular risk factors and
other available HF confounding risk factors did not change significantly the association with
HF events, although part of the risk seemed to be mediated by cardiovascular risk factors as
point estimates were decreased in multivariate models. Excluding participants using thyroid
medications (mainly thyroxine replacement) at baseline and during follow-up further
increased the risks.
To our knowledge, this is the first individual participant data analysis of large cohorts
examining the association between subclinical thyroid dysfunction and HF events. Our
findings are consistent with previous observational studies15, 16, 18 that reported a higher
incidence and recurrent risks of HF among participants with higher TSH levels in
comparison with euthyroid participants; our individual participant data analysis assessed this
risk across a larger age range and several subgroups. The Health, Aging and Body
Composition Study previously reported an increased risk of HF events among subjects with
TSH ≥7.0 mIU/L (HR 2.58, CI 1.19–5.60 for TSH 7.0–9.9 mIU/L and HR 3.26, CI 1.37–
7.77 for TSH ≥10.0 mIU/L) over 4-year follow-up, with a higher risk for recurrent HF
events among those with preexisting HF (HR 7.62, CI 2.25–25.77);15 these data were
updated with 8-year follow-up in the current analysis. The Cardiovascular Health Study
reported 16 an increased risk of HF events among subjects with TSH ≥10.0 mIU/L (HR 1.88;
CI 1.05–3.34) over 12-year follow-up; these data were updated with 14-year follow-up in
the present data. The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)
study18 recently reported an increased risk of HF hospitalization among subjects with TSH
≥10.0 mIU/L (HR 3.01, CI 1.12–8.11) and among those with suppressed TSH <0.10 mIU/L
(HR 4.61, CI 1.71–12.47). The Bari study that examined only patients with preexisting HF17
reported an increased risk of recurrent HF events among participants with subclinical
hypothyroidism (HR 2.03, CI 1.16–3.55), but without a categorization of TSH levels. We
previously found similar pattern with an increased risk of CHD mortality among participants
with subclinical hypothyroidism and subclinical hyperthyroidism, particularly in those with
more severe thyroid dysfunction.12, 13 The present data and these previous studies suggest
that clinical thyroid dysfunction varies over the spectrum of TSH level and the risk of HF
was proportional to the degree of TSH elevation and suppression.
Thyroid hormones play an important function in the homeostasis of the cardiovascular
system with an impact on cardiac output, cardiac contractility, vascular resistance and blood
pressure. 9 Subclinical hypothyroidism has been associated with left ventricular diastolic
dysfunction at rest and during exertion and impaired left ventricular systolic function on
exercise. Higher TSH levels among participants with subclinical hypothyroidism have been
correlated with a decrease stroke volume of left ventricular, a decrease in the cardiac index
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and an increase in systemic vascular resistance.19 Isolated ventricular diastolic dysfunction
is associated with the clinical manifestation of HF,33 and might explained the associated risk
of HF events reported in our study with higher TSH levels in subclinical hypothyroidism.
The increased risk of CHD events with subclinical hypothyroidism13 might also contribute
to the development of HF, as CHD is a common etiology of HF.34, 35 Restoration of a
euthyroid state in patients with subclinical hypothyroidism has been associated with
normalization of some structural cardiac parameters 36, 37 and one randomized controlled
trial found that thyroxine therapy in patients with subclinical hypothyroidism reduced the
preejection period-left ventricular ejection time ratio,38 but no large RCT of the impact of
thyroxine therapy on HF events has been conducted yet. Only few studies, in contrast with
overt hyperthyroidism, reported an effect of endogenous subclinical hyperthyroidism on
cardiac parameters: an increased average heart rate, a higher left ventricular mass and an
impaired diastolic function.20 Two longitudinal studies reported higher rates of atrial
fibrillation with subclinical hyperthyroidism,25, 39 which might predispose to the
development of heart failure. Recently, an individual participant analysis has reported an
increased risk of atrial fibrillation among participants with subclinical hyperthyroidism with
greater risks in those with TSH < 0.10 mIU/L.12
Among the strengths of our study, our individual participant data analysis included all
available cohorts with data on subclinical thyroid dysfunction and HF, and this design is
considered the optimal method to perform time-to-event analyses, to avoid biases associated
with subgroups analysis (ecology fallacy) and standardize definitions of predictors,
outcomes, and adjustment for potential confounders.13, 24, 28
Our study had several limitations. First, thyroid function was measured at baseline, and the
possible progression from subclinical to overt dysfunction was unknown, which is a
limitation of all published observational studies.15, 25, 27 In addition, FT3 was measured in
only two cohorts, and thus was not included in the definition of subclinical hyperthyroidism
in main analyses; sensitivity analyses excluding those with abnormal FT3 yielded similar
results. Second, HF events were mainly related to hospitalizations, which might lower rates
of HF events. Because some patients might develop heart failure without hospitalization, the
rate of recorded HF event is likely underestimated.15, 40 Although we considered a
homogeneous definition of HF, possible misclassification of HF events might have occurred,
because HF is difficult to define and adjudication might vary across large-population
studies,41 such misclassification was probably non-differential, as all HF outcome
adjudication were blinded to thyroid status; non-differential misclassification would lower
any potential associations. Even with the large number of individual participants, some
subgroup analyses, particularly among those younger than 50 years and those with
preexisting HF had limited power because of the limited number of participants with HF
events. We cannot exclude that some interaction or trend tests might not be significant due
to lack of power. Particularly a possible effect of gender and race might be explored in
future larger studies. Finally, the studied population had limited data on young adults and
non-white populations, which limits the generalization of our results to the entire population.
In conclusion, the combination of all available large prospective cohorts with 25,378
participants suggests that the risk of HF increased both with lower and higher TSH levels,
particularly in those with TSH levels ≥10.0 mIU/L and in those with TSH <0.10 mIU/L. For
the majority of participants with minimal TSH disturbances (TSH levels between 4.50–6.99
mIU/L and TSH levels between 0.10–0.44 mIU/L), the risk of HF was not increased
compared to euthyroid participants. Similar to previous studies,13 we found that subclinical
thyroid dysfunction is a heterogeneous entity with varying risks of cardiovascular disease
according to TSH levels. The ACC/AHA Guidelines for the Diagnosis and Management of
HF in Adults recommend the measuring thyroid function to investigate conditions that might
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exacerbate HF but without specifying the potential impact of different TSH levels. 88 Our
findings contribute to a better interpretation of TSH levels in the prevention and
investigation of HF. Pending results from RCTs, the findings of our study might be useful to
define the TSH threshold for thyroid medication among participants with subclinical thyroid
dysfunction, although clinical decision based only on observational studies should be used
with great caution, as they are subject to limitations. No clinical trial has assessed yet
whether treating subclinical hypothyroidism improved HF outcome. Given the high
prevalence of subclinical hypothyroidism and HF in the elderly, thyroxine replacement
should be investigated with appropriately powered randomized controlled trials with clinical
HF outcomes.
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Clinical perspective
Analysis of individual participant data from all available prospective cohorts suggests
that the risk of heart failure (HF) is increased both with higher and lower levels of
Thyroid Stimulating Hormone (TSH) compared to normal range, particularly in those
with TSH levels ≥ 10.0 mIU/L or < 0.10 mIU/L. These findings might lead to a better
interpretation of TSH levels, as the latest ACC/AHA guidelines for the Diagnosis and
Management of HF in Adults recommend measurement of thyroid function to investigate
conditions that might exacerbate HF without specifying the clinical impact of different
TSH levels. In the absence of randomized controlled trials that would give definitive
evidence about the impact of treatment on HF, our findings might be useful to define
TSH threshold for thyroid medication, although clinical decision only based on
observational studies should be used with great caution. To definitively clarify this issue,
a randomized controlled trial (TRUST trial, www.trustthyroidtrial.com) has just been
started in Europe among elderly with subclinical hypothyroidism to assess the impact of
thyroxine replacement therapy on cardiovascular outcomes, including HF events
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Figure 1.
Hazard Ratios for Heart Failure Events According to Thyroid-Stimulating Hormone Levels.
Abbreviations: CI: Confidence Interval; HF: Heart Failure; HR: Hazard Ratio; TSH:
Thyroid-Stimulating Hormone. Age- and gender-adjusted HRs and their 95% CI are
represented by squares. Squares to the right of the solid lines indicate increased risk of HF
events. Sized of data markers are proportional to the inverse of the variance of the HRs.
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